Substantial doubt about the company's ability to continue as a going concern.
“Our management concluded that our recurring losses from operations, existing unrestricted cash, and cash equivalents raise substantial doubt about our ability to continue as a going concern for the next twelve months after issuance of our financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Oct 28, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
DBV Technologies submitted a BLA for children age 4 through 7 and expects the toddler BLA in 2027. It ended the third quarter with 165.7 million U.S. dollars, funding operations into the third quarter of 2027.
DBV Technologies S.A. submitted the VIASKIN Peanut Patch BLA for children aged 4 through 7 years on September 29, 2026 and requested Priority Review. Third-quarter net loss was $64.5 million, and substantial doubt exists about its ability to continue as a going concern.
DBV Technologies S.A. submitted its BLA for VIASKIN Peanut in children ages 4 through 7 on September 29, 2026, requested Priority Review, and reported a $162.5 million nine-month net loss, $165.7 million cash, and runway into the third quarter of 2027.
DBV Technologies submitted a Biologics License Application to the U.S. Food and Drug Administration for the VIASKIN® Peanut Patch for children with peanut allergy aged 4 through 7 years, requesting Priority Review; the application is supported by positive Phase 3 VITESSE results in 654 children.
